Puma Biotechnology Stock Market Outlook
| PBYI Stock | USD 6.43 0.11 1.74% |
Under 68 percent of all Puma Biotechnology's traders are curious in acquiring. The analysis of the overall investor sentiment regarding Puma Biotechnology suggests that a large number of traders are confidant. Puma Biotechnology's investing sentiment shows overall attitude of investors towards Puma Biotechnology.
Comfort Level 68
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Puma Biotechnology's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Puma Biotechnology.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Puma Biotechnology is 'Hold'. The recommendation algorithm takes into account all of Puma Biotechnology's available fundamental, technical, and predictive indicators you will find on this site.
Execute Puma Biotechnology Buy or Sell Advice
The Puma recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Puma Biotechnology. Macroaxis does not own or have any residual interests in Puma Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Puma Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Fair | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Puma Biotechnology Trading Alerts and Improvement Suggestions
| Puma Biotechnology appears to be risky and price may revert if volatility continues | |
| About 72.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand |
Puma Biotechnology Returns Distribution Density
The distribution of Puma Biotechnology's historical returns is an attempt to chart the uncertainty of Puma Biotechnology's future price movements. The chart of the probability distribution of Puma Biotechnology daily returns describes the distribution of returns around its average expected value. We use Puma Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Puma Biotechnology returns is essential to provide solid investment advice for Puma Biotechnology.
| Mean Return | 0.42 | Value At Risk | -3.85 | Potential Upside | 5.81 | Standard Deviation | 4.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Puma Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Puma Stock Institutional Investors
| Shares | Lsv Asset Management | 2025-06-30 | 535.7 K | Citadel Advisors Llc | 2025-06-30 | 507.8 K | Globeflex Capital, L.p. | 2025-06-30 | 452.6 K | Arrowstreet Capital Limited Partnership | 2025-06-30 | 451.6 K | Los Angeles Capital Management Llc | 2025-06-30 | 445.5 K | O'shaughnessy Asset Management Llc | 2025-06-30 | 437.7 K | Sei Investments Co | 2025-06-30 | 347.2 K | Bank Of New York Mellon Corp | 2025-06-30 | 344.1 K | Millennium Management Llc | 2025-06-30 | 334.6 K | Blackrock Inc | 2025-06-30 | 3.8 M | Vanguard Group Inc | 2025-06-30 | 3.7 M |
Puma Biotechnology Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | (22.2M) | 3.5M | 7.9M | (15.4M) | (13.8M) | (13.1M) | |
| Free Cash Flow | 20.7M | (22.8M) | 14.4M | 38.9M | 44.7M | 46.9M | |
| Other Non Cash Items | 7.1M | 7.0M | 1.5M | (519K) | (596.9K) | (567.0K) | |
| Capital Expenditures | 1K | 7M | 12.6M | 56K | 64.4K | 61.2K | |
| Net Income | (29.1M) | 2K | 21.6M | 30.3M | 27.3M | 28.6M | |
| End Period Cash Flow | 75.3M | 78.8M | 86.7M | 71.3M | 82.0M | 71.9M | |
| Change To Inventory | (3.7M) | 2.6M | (2.6M) | (1.6M) | (1.5M) | (1.6M) | |
| Depreciation | 11.3M | 9.8M | 11.5M | 11.5M | 13.3M | 13.9M | |
| Change To Netincome | 66.6M | 37.6M | 39.8M | 18.8M | 21.7M | 20.6M | |
| Change Receivables | (8.1M) | 2.4M | (6.0M) | (7.8M) | (7.0M) | (6.7M) | |
| Investments | (10.9M) | 14.1M | (22.8M) | (20.4M) | (23.5M) | (22.3M) |
Puma Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Puma Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Puma Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Puma stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.40 | |
β | Beta against Dow Jones | 0.28 | |
σ | Overall volatility | 4.76 | |
Ir | Information ratio | 0.08 |
Puma Biotechnology Volatility Alert
Puma Biotechnology exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Puma Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Puma Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Puma Biotechnology Fundamentals Vs Peers
Comparing Puma Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Puma Biotechnology's direct or indirect competition across all of the common fundamentals between Puma Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Puma Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Puma Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Puma Biotechnology to competition |
| Fundamentals | Puma Biotechnology | Peer Average |
| Return On Equity | 0.4 | -0.31 |
| Return On Asset | 0.099 | -0.14 |
| Profit Margin | 0.17 % | (1.27) % |
| Operating Margin | 0.18 % | (5.51) % |
| Current Valuation | 265.59 M | 16.62 B |
| Shares Outstanding | 50.39 M | 571.82 M |
| Shares Owned By Insiders | 15.38 % | 10.09 % |
| Shares Owned By Institutions | 71.71 % | 39.21 % |
| Number Of Shares Shorted | 3.59 M | 4.71 M |
| Price To Earning | 18.52 X | 28.72 X |
| Price To Book | 2.77 X | 9.51 X |
| Price To Sales | 1.53 X | 11.42 X |
| Revenue | 230.47 M | 9.43 B |
| Gross Profit | 163.04 M | 27.38 B |
| EBITDA | 48.08 M | 3.9 B |
| Net Income | 30.28 M | 570.98 M |
| Cash And Equivalents | 77.96 M | 2.7 B |
| Cash Per Share | 1.71 X | 5.01 X |
| Total Debt | 74.08 M | 5.32 B |
| Debt To Equity | 5.19 % | 48.70 % |
| Current Ratio | 2.04 X | 2.16 X |
| Book Value Per Share | 2.29 X | 1.93 K |
| Cash Flow From Operations | 38.92 M | 971.22 M |
| Short Ratio | 9.67 X | 4.00 X |
| Earnings Per Share | 0.74 X | 3.12 X |
| Price To Earnings To Growth | 0.03 X | 4.89 X |
| Target Price | 5.0 | |
| Number Of Employees | 172 | 18.84 K |
| Beta | 1.18 | -0.15 |
| Market Capitalization | 324.01 M | 19.03 B |
| Total Asset | 213.33 M | 29.47 B |
| Retained Earnings | (1.31 B) | 9.33 B |
| Working Capital | 51.55 M | 1.48 B |
Note: Disposition of 4540 shares by Maximo Nougues of Puma Biotechnology at 5.844 subject to Rule 16b-3 [view details]
Puma Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Puma . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Puma Biotechnology Target Price Consensus
Puma target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Puma Biotechnology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Hold |
Most Puma analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Puma stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Puma Biotechnology, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPuma Biotechnology Target Price Projection
Puma Biotechnology's current and average target prices are 6.43 and 5.00, respectively. The current price of Puma Biotechnology is the price at which Puma Biotechnology is currently trading. On the other hand, Puma Biotechnology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Puma Biotechnology Market Quote on 30th of January 2026
Target Price
Analyst Consensus On Puma Biotechnology Target Price
Puma Biotechnology Analyst Ratings
Puma Biotechnology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Puma Biotechnology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Puma Biotechnology's financials, market performance, and future outlook by experienced professionals. Puma Biotechnology's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Puma Biotechnology Buy or Sell Advice
When is the right time to buy or sell Puma Biotechnology? Buying financial instruments such as Puma Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Puma Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Puma Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.